Discontinued — last reported Q4 '24
Products & Services · Contract with customer, liability
Licensing and royalty revenue — Contract with customer, liability
Moderna Licensing and royalty revenue — Contract with customer, liability decreased by 38.5% to $8.00M in Q4 2024 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2023
Last reportedQ4 2024Feb 21, 2025
Rolls up toContract Liabilities
How to read this metric
A higher balance indicates a larger backlog of future revenue to be recognized as performance obligations are met over time.
Detailed definition
This metric represents the outstanding balance of deferred revenue or contract liabilities arising from licensing and ro...
Peer comparison
Comparable to 'deferred revenue' or 'contract liabilities' on the balance sheet for companies with multi-year licensing contracts.
Metric ID:
mrna_segment_licensing_and_royalty_revenue_contract_with_customer_liabilityHistorical Data
4 periods
| Q4 '23 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|
| Value | $0.00 | $20.00M | $13.00M | $8.00M |
| QoQ Change | — | — | -35.0% | -38.5% |
Range$0.00 – $20.00M
Current Streak2+ quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Moderna's licensing and royalty revenue — contract with customer, liability?
- Moderna (MRNA) reported licensing and royalty revenue — contract with customer, liability of $8.00M in Q4 2024.
- What does licensing and royalty revenue — contract with customer, liability mean?
- The total amount of money received from partners for licensing that has not yet been recognized as revenue.